ATE480565T1 - Chimere anti-cd44-antikörper und deren verwendung zur behandlung von akuter myeloischer leukämie - Google Patents

Chimere anti-cd44-antikörper und deren verwendung zur behandlung von akuter myeloischer leukämie

Info

Publication number
ATE480565T1
ATE480565T1 AT04803792T AT04803792T ATE480565T1 AT E480565 T1 ATE480565 T1 AT E480565T1 AT 04803792 T AT04803792 T AT 04803792T AT 04803792 T AT04803792 T AT 04803792T AT E480565 T1 ATE480565 T1 AT E480565T1
Authority
AT
Austria
Prior art keywords
antibodies
acute myeloid
chimere
treatment
myeloid leukemia
Prior art date
Application number
AT04803792T
Other languages
English (en)
Inventor
Florence Smadja
John Dick
Jean Kadouche
Laurence Boumsell
Original Assignee
Inst Nat Sante Rech Med
Univ Health Network
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med, Univ Health Network filed Critical Inst Nat Sante Rech Med
Application granted granted Critical
Publication of ATE480565T1 publication Critical patent/ATE480565T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2884—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD44
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT04803792T 2003-11-19 2004-11-19 Chimere anti-cd44-antikörper und deren verwendung zur behandlung von akuter myeloischer leukämie ATE480565T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03292873A EP1532984A1 (de) 2003-11-19 2003-11-19 Verwendung von Antikörpern gegen CD44 zur Ausrottung der Stammzellen in akute myeloide Leukämie
PCT/EP2004/014157 WO2005049082A2 (en) 2003-11-19 2004-11-19 Chimeric anti cd44 antibodies and their use for treating acute myeloid leukemia

Publications (1)

Publication Number Publication Date
ATE480565T1 true ATE480565T1 (de) 2010-09-15

Family

ID=34429570

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04803792T ATE480565T1 (de) 2003-11-19 2004-11-19 Chimere anti-cd44-antikörper und deren verwendung zur behandlung von akuter myeloischer leukämie

Country Status (10)

Country Link
US (4) US20050147606A1 (de)
EP (3) EP1532984A1 (de)
JP (1) JP2007513610A (de)
KR (1) KR20060126659A (de)
CN (1) CN1898268A (de)
AT (1) ATE480565T1 (de)
AU (1) AU2004290918B2 (de)
CA (2) CA2484459A1 (de)
DE (1) DE602004029078D1 (de)
WO (1) WO2005049082A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8071072B2 (en) * 1999-10-08 2011-12-06 Hoffmann-La Roche Inc. Cytotoxicity mediation of cells evidencing surface expression of CD44
US20080118518A1 (en) * 2006-09-07 2008-05-22 Cirrito Thomas P Cancer stem cell-targeted cancer therapy
EP2079484A4 (de) * 2006-09-07 2010-03-17 Stemline Therapeutics Inc Überwachung von krebsstammzellen
UY30776A1 (es) * 2006-12-21 2008-07-03 Medarex Inc Anticuerpos cd44
EP2009028A1 (de) * 2007-06-27 2008-12-31 Monoclonal Antibodies Therapeutics Kombination einer konventionellen Antikrebsbehandlung mit einer Verabreichung von Antikörpern gegen CD44 zur Behandlung fester Tumore
CN101368173B (zh) * 2008-04-09 2011-12-28 协和干细胞基因工程有限公司 抗人cd44的工程抗体、载体、试剂盒及其用途
EP2403518A4 (de) * 2009-03-06 2013-01-23 Angstrom Pharmaceuticals Inc Zusammensetzungen und verfahren zur modulation der zellmigration
JP5763105B2 (ja) * 2010-02-04 2015-08-12 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 頭頸部扁平上皮癌の治療に使用されるｃｄ４４に対するモノクローナル抗体
JP2014502258A (ja) * 2010-10-22 2014-01-30 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド 免疫反応を抑制するためにプログラムされた制御性ｔ細胞の発見
MX2014004969A (es) * 2011-10-26 2014-05-30 Univ California Anticuerpo monoclonal cd44 para el tratamiento de leucemia linfocita cronica de celulas b y otros padecimientos malignos hematologicos.
US20150151004A1 (en) * 2013-06-14 2015-06-04 The University Of Kansas Methods and compositions of modulating tumor initiating cells and the use thereof
NL2011904C2 (en) * 2013-12-06 2015-06-09 Stichting Vu Vumc Leukemic stem cell markers.
CN111542341A (zh) * 2017-10-25 2020-08-14 锕医药股份有限公司 基于抗-cd45的淋巴细胞消减方法及其与基于act的癌症疗法的联合应用
EP4103610A1 (de) * 2020-02-13 2022-12-21 UCB Biopharma SRL Anti-cd4-ctla4 bispezifische antikörper
CN113552363B (zh) * 2020-04-03 2024-03-08 中国科学院广州生物医药与健康研究院 Cd44作为造血干/祖细胞的标志物及其应用
JP2023526529A (ja) 2020-05-19 2023-06-21 アンスティテュ・クリー サイトカイン放出症候群の診断及び処置の方法
AU2022278013A1 (en) 2021-05-18 2024-01-18 Janssen Biotech, Inc. Compositions comprising a t cell redirection therapeutic and an anti-cd44 therapeutic
CN114213538B (zh) * 2021-12-24 2022-07-08 北京市神经外科研究所 Cd44抗体、嵌合抗原受体及其应用
CN114316049B (zh) * 2021-12-24 2022-08-09 北京市神经外科研究所 Cd44抗体、嵌合抗原受体及其应用
WO2024040195A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024170543A1 (en) 2023-02-14 2024-08-22 Institut National de la Santé et de la Recherche Médicale Anti-cd44 antibodies and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5543594A (en) * 1992-10-30 1994-05-24 Duke University An adhesion molecule
FR2715664B1 (fr) 1994-01-31 1996-04-12 Proteine Performance Sa Baculovirus recombinant et son utilisation pour la production d'anticorps monoclonaux.
US6492332B1 (en) * 1995-12-12 2002-12-10 Omeros Corporation Irrigation solution and methods for inhibition of tumor cell adhesion, pain and inflammation
ES2176574T3 (es) * 1996-09-03 2002-12-01 Gsf Forschungszentrum Umwelt Utilizacion de anticuerpos bi y triespecificos para la induccion de inmunidad tumoral.
JPH10301492A (ja) * 1997-04-23 1998-11-13 Sony Corp 暗号化装置および方法、復号装置および方法、並びに情報処理装置および方法
CN100423041C (zh) * 2000-01-21 2008-10-01 索尼公司 数据处理设备和数据处理方法
TW538636B (en) * 2000-09-01 2003-06-21 Matsushita Electric Ind Co Ltd Reproduction equipment, reproduction equipment specifying equipment, reproduction equipment specifying system and methods and recording media for said equipment and system
US6972324B2 (en) * 2001-05-18 2005-12-06 Boehringer Ingelheim Pharmaceuticals, Inc. Antibodies specific for CD44v6
ATE382060T1 (de) * 2001-06-01 2008-01-15 Biogen Idec Inc Moleküle und verfahren zur inhibierung der freisetzung von kim-1

Also Published As

Publication number Publication date
JP2007513610A (ja) 2007-05-31
EP1692183B1 (de) 2010-09-08
DE602004029078D1 (de) 2010-10-21
US20050147606A1 (en) 2005-07-07
CA2484459A1 (en) 2005-05-19
US20070184051A1 (en) 2007-08-09
US20070237761A1 (en) 2007-10-11
AU2004290918B2 (en) 2012-03-08
WO2005049082A3 (en) 2005-11-10
AU2004290918A1 (en) 2005-06-02
WO2005049082A2 (en) 2005-06-02
CA2546566A1 (en) 2005-06-02
US20100040540A1 (en) 2010-02-18
EP2275444A1 (de) 2011-01-19
EP1532984A1 (de) 2005-05-25
EP1692183A2 (de) 2006-08-23
CN1898268A (zh) 2007-01-17
KR20060126659A (ko) 2006-12-08

Similar Documents

Publication Publication Date Title
ATE480565T1 (de) Chimere anti-cd44-antikörper und deren verwendung zur behandlung von akuter myeloischer leukämie
ATE454903T1 (de) Gegen menschliches ovarialkarzinom und gegen cd3 gerichteter bispezifischer antikörper
GEP20074222B (en) Antibodies to cd40
MX9504802A (es) Anticuerpos anti-egfr y fvs de cadena simple anti-egfr.
ATE509955T1 (de) Humanisierte kollagen-antikörper und damit verbundene verfahren
CY1110033T1 (el) Τεχνητα ανθρωπινα θεραπευτικα αντισωματα εναντια σε ισομορφες cd45
EA200501891A1 (ru) Гуманизированные антитела, распознающие бета-амилоидный пептид
IL173323A0 (en) Antibodies directed to parathyroid hormone (pth) and uses thereof
DK1827492T3 (da) Antistoffer rettet mod GPNMB og anvendelser deraf
ATE472556T1 (de) Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
NO20053435L (no) Immunoglobulinvarianter og anvendelser derav
CY1110963T1 (el) Εξανθρωπισμενα αντισωματα που αναγνωριζουν πεπτιδιο βητα αμυλοειδους
WO2004029093A3 (en) Humanized anti-granulocyte mn-3 antibody and uses thereof
HRP20090527T1 (en) Nogo-a neutralising immunoglobulins for treatment of neurological diseases
NZ594466A (en) Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies
BR0112086A (pt) Anticorpos para mcp-1 humano
HUP0401560A2 (hu) Terápiás kötőmolekulák
ATE495751T1 (de) Behandlung von bauchspeicheldrüsenkrebs mit einem monoklonalen antikörper
ATE372349T1 (de) Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen
ATE478095T1 (de) Konjugate mit einem für die ed-b-domäne von fibronectin spezifischen antikörper, und deren verwendung zum nachweis und zur behandlung von tumoren
TH83888B (th) ฮิวแมไนซ์ แอนติบอดี้ ที่จำเพาะต่อเบต้า อมายลอยด์ เปปไตด์
WO2004034974A3 (en) Anti-reg iϝ antibody for treatment of colon cancer

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties